Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine

Pneumococcal Infections Clinical Trial

Official title:

A Randomized, Double-blind, Positive-controlled Phase Ⅳ Clinical Trial to Evaluate the Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide Vaccine in Population Aged 2 Years and Older

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05477693
• Other study ID #: PRO-PPV-4002
• Status: Completed
• Phase: Phase 4
• Start date: October 25, 2022
• Est. completion date: April 10, 2023

Study information

• Verified date: April 2022
• Source: Sinovac Biotech Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomized, double-blind, positive-controlled phase Ⅳ clinical trial of 23-valent pneumococcal polysaccharide vaccine manufactured by Sinovac Biotech Co., Ltd.The purpose of this study is to evaluate the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine in population aged 2 years and older.

Description:

This study is a randomized, double-blind, positive-controlled phase Ⅳ clinical trial to evaluate the immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine in population aged 2 years and older.The experimental vaccine was manufactured by Sinovac Biotech Co., Ltd,the control vaccine was manufactured by Merck Sharp & Dohme.A total of 1800 subjects including 900 subjects aged 2~17 years,360 subjects aged 18~59 years and 540 subjects aged 60 years and above will be enrolled.Subjects in each age group will be randomly divided into two groups according to the ratio of 2:1, and received one dose of experimental vaccine or control vaccine.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1800
• Est. completion date: April 10, 2023
• Est. primary completion date: April 10, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 2 Years and older

Eligibility

Inclusion Criteria:

• Children aged 2 years and above in stable health;
• The subjects and/or guardians can understand and voluntarily sign the informed consent form (For subjects aged 8-17 years, both subjects and guardians need to sign the informed consent form.If the subject aged 16 to 17 years with full capacity for civil conduct and his/her labor income is his/her main source of living, the informed consent can be signed only by the subject himself/herself);
• Proven legal identity.

Exclusion Criteria:

• Have received any pneumococcal vaccine;
• History bacterial pneumonia or invasive pneumococcal infectious diseases caused by pneumococci and confirmed by culture.
• Women of childbearing age (menarche to premenopause) are pregnant (including positive urine pregnancy test), breastfeeding or planning pregnancy within 1 month;
• History of asthma, allergy to vaccines or vaccine components, and serious adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema;
• Severe chronic diseases,such as severe cardiovascular diseases, hypertension(Systolic blood pressure =140mmHg and/or diastolic blood pressure =90mmHg) and diabetes that cannot be controlled by drugs, liver or kidney diseases,malignant tumors, etc.;
• Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;
• Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets) or obvious bruising or blood coagulation;
• Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding allergic rhinitis corticosteroid spray therapy, acute noncomplicated dermatitis superficial corticosteroid therapy) in the past 6 months;
• A long history of alcohol or drug abuse;
• Receipt of blood products within in the past 3 months;
• Receipt of other investigational drugs within 30 days prior to receiving the investigational vaccine;
• Receipt of attenuated live vaccines or COVID-19 vaccines in the past 14 days;
• Receipt of inactivated or subunit vaccines in the past 7 days;
• Onset of various acute or chronic diseases within 3 days prior to the study;
• Underarm body temperature before vaccination>37.0°C;
• The subjects participated in other clinical trials during the follow-up period or will be planned to participate other clinical trials within 1 months;
• According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.

Related Conditions & MeSH terms

• Pneumococcal Infections

Intervention

Biological:
• Experimental 23-valent PPV
The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.25µg each for serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B,17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in 0.5 mL of sodium chloride, sodium dihydrogen phosphate and disodium hydrogen phosphate per injection.
• Control 23-valent PPV
The control vaccine was manufactured by Merck Sharp & Dohme, Ltd. Purified capsular polysaccharides from 23 Streptococcus in 0.5 mL of pneumoniae types 0.25% phenol and sodium chloride.

Locations

Country	Name	City	State
China	Linwei District Center for Disease Control and Prevention	Weinan	Shanxi

Sponsors (1)

Lead Sponsor	Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunogenicity index-Seroconversion rate (2-fold increase rate)	Seroconversion rate (2-fold increase rate)for serotype specificity (3, 6B, 14, 19A, 19F, 23F) of pneumococcal immunoglobulin G (IgG) antibody 30 days after vaccination.	30 days after vaccination
Secondary	Immunogenicity index-Geometric Mean Concentration (GMC)	Geometric Mean Concentration (GMC) for serotype specificity (3, 6B, 14, 19A, 19F, 23F) of pneumococcal IgG antibody 30 days after vaccination.	30 days after vaccination
Secondary	Immunogenicity index-Geometric Mean Increase (GMI)	Geometric Mean Increase (GMI) for serotype specificity (3, 6B, 14, 19A, 19F, 23F) of pneumococcal IgG antibody 30 days after vaccination.	30 days after vaccination
Secondary	Immunogenicity index-Seroconversion rate	Seroconversion rate for serotype specificity (1?2?4?5?7F?8?9N?9V?10A?11A?12F?15B?17F?18C?20?22F and 33F)of pneumococcal IgG antibody 30 days after vaccination.	30 days after vaccination
Secondary	Immunogenicity index-GMC	Geometric Mean Concentration (GMC) for serotype specificity (1?2?4?5?7F?8?9N?9V?10A?11A?12F?15B?17F?18C?20?22F and 33F)of pneumococcal IgG antibody 30 days after vaccination.	30 days after vaccination
Secondary	Immunogenicity index-GMI	Geometric Mean Increase (GMI) for serotype specificity (1?2?4?5?7F?8?9N?9V?10A?11A?12F?15B?17F?18C?20?22F and 33F)of pneumococcal IgG antibody 30 days after vaccination.	30 days after vaccination
Secondary	Safety index-Incidence of adverse reactions	Incidence of adverse reactions within 30 days after vaccination.	Within 30 days after vaccination
Secondary	Safety index-incidence of adverse reactions	Incidence of adverse reactions within 7 days after vaccination	Within 7 days after vaccination
Secondary	Safety index-Incidence of serious adverse events	Incidence of serious adverse events within 30 days after vaccination.	Within 30 days after vaccination